NCT00733200
- Conditions
- Adenocarcinoma, Carcinoma, Cholangiocarcinoma, +5 more
- Locations
-
Not specified
Clinical trial condition
Cholangiocarcinoma
Explore clinical trials studying Cholangiocarcinoma. Study availability and eligibility vary by location and protocol.
490 public trials
154 recruiting studies
Cholangiocarcinoma trial results
NCT00350753
- Conditions
- Adenocarcinoma, Biliary Tract Diseases, Biliary Tract Neoplasms, +11 more
- Locations
-
- Århus Sygehus Aarhus, Denmark
- Rigshospitalet Copenhagen, Denmark
- Odense University Hospital Odense, Denmark
NCT00350961
- Conditions
- Adenocarcinoma, Carcinoma, Cholangiocarcinoma, +3 more
- Locations
-
- Rigshospitalet Copenhagen, Denmark
- Vejle Sygehus Vejle, Denmark
NCT00168987
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +17 more
- Locations
-
- Charite University Hospital Berlin, Germany
NCT00123825
- Conditions
- Adenocarcinoma, Biliary Tract Cancer, Biliary Tract Diseases, +12 more
- Locations
-
- Massachusetts General Hospital Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
- Dana-Farber Cancer Institute Boston, Massachusetts, United States
NCT00041808
- Conditions
- Adenocarcinoma, Breast Diseases, Breast Neoplasms, +49 more
- Locations
-
- Scripps Stevens Cancer Division San Diego, California, United States
- UCSF Cancer Center San Francisco, California, United States
- Scott and White Clinic Temple, Texas, United States
- Frankfurt Universtiy Frankfurt, Germany
Active, Not Recruiting
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.
NCT06506955
- Conditions
- Adenocarcinoma, Advanced/Metastatic Cancer, Carcinoma, +8 more
- Locations
-
- University of California, San Francisco (UCSF) San Francisco, California, United States
- Institut Paoli-Calmettes Marseille, France
- Institut De Cancerologie Strasbourg Strasbourg, France
- Severance Hospital Seoul, South Korea
Active, Not Recruiting
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
NCT04521686
- Conditions
- Adenocarcinoma, Any Solid Tumor, Astrocytoma, +49 more
- Locations
-
- Mayo Clinic of Scottsdale Phoenix, Arizona, United States
- The University of Arizona Cancer Center Tucson, Arizona, United States
- USC Norris Cancer Hospital Los Angeles, California, United States
- Mayo Clinic in Florida Jacksonville, Florida, United States
Active, Not Recruiting
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185
- Conditions
- Adenocarcinoma, Adnexal Diseases, Advanced Solid Tumor, +53 more
- Locations
-
- University of Alabama at Birmingham Birmingham, Alabama, United States
- Mayo Clinic Phoenix, Arizona, United States
- City of Hope Duarte, California, United States
- University of California, Los Angeles (UCLA) Santa Monica, California, United States
Active, Not Recruiting
Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer
NCT05277766
- Conditions
- Abdominal Neoplasms, Adenocarcinoma, Appendiceal Neoplasms, +37 more
- Locations
-
- UZ Ghent Ghent, East-Flanders, Belgium